

Change in substantial shareholder notice

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development company, advises that the attached Change in Substantial Shareholder Notice lodged by Chairman, Dr Stewart Washer relates to purchases made since the lodgement of his last notice and for dilution due to the recently completed placement.

This announcement has been approved and authorised for release by Stewart Washer.

For further information:

Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. **Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical and real-world evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Form 604
Corporations Law
671B

Notice of change in interests of substantial holder

To: Company Name/Scheme: Emyria Limited

ACN/ARSN 625 085 734

1. Details of substantial holder⁽¹⁾

Name Dr Stewart James Washer & Dr Patrizia Derna Washer
ACN/ARSN (if applicable) _____

There was a change in the interests of the substantial holder on 22/12/2020

The previous notice was given to the company on 17/09/2020

The previous notice was dated 17/09/2020

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate⁽²⁾ had a relevant interest⁽³⁾ in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities ⁽⁴⁾	Previous notice		Present notice	
	Person's votes	Voting power ⁽⁵⁾	Person's votes	Voting power ⁽⁵⁾
Ordinary Shares	48,550,499	22.9%	49,325,599	21.87%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change ⁽⁶⁾	Consideration given in relation to change ⁽⁷⁾	Class and number of securities affected	Person's votes affected
22/12/2020	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Trust>	Dilution due to placement	-	49,325,599	49,325,599
09/11/2020	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Purchase	\$20,765.65	270,000	270,000

10/11/2020	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Purchase	\$7,986.90	100,000	100,000
11/11/2020	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Purchase	\$12,283.65	150,000	150,000
12/11/2020	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Purchase	\$20,321.22	255,000	255,000

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Trust>	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Trust>	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Trust>	28,400,000
Dr Stewart James Washer	Mal Washer Nominees Pty Ltd <Mal Washer Family No1 A/C>	Mal Washer Nominees Pty Ltd <Mal Washer Family No1 A/C>	19,600,000
Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Superannuation Fund>	1,325,599

5. Changes in association

The persons who have become associates⁽²⁾ of, ceased to be associates of, or have change the nature of their association⁽⁹⁾ with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Dr Stewart James Washer & Dr Patrizia Derna Washer <The Washer Family Trust>	14 Coogee Street Mount Hawthorn WA 6016
Mal Washer Nominees Pty Ltd <Mal Washer Family No1 A/C>	85 Carabooda Road Carabooda WA 6033

Dr Stewart James Washer & Dr Patrizia Derna Washer
<The Washer Family Superannuation Fund>

14 Coogee Street Mount Hawthorn WA 6016

Signature

print name Stewart Washer

capacity

sign here



date 3 February 2021

DIRECTIONS

⁽¹⁾ If there are a number of substantial holders with similar or related relevant interests (eg a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.

⁽²⁾ See the definition of "associate" in section 9 of the Corporations Law.

⁽³⁾ See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Law.

⁽⁴⁾ The voting shares of a company constitute one class unless divided into separate classes.

⁽⁵⁾ The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

⁽⁶⁾ Include details of:

- (a) any relevant agreement or other circumstance because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
- (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Law.

⁽⁷⁾ Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

⁽⁹⁾ Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.